After months of speculation Sanofi-Aventis, the French pharma major, at the weekend unveiled an all-cash $69.00 a share bid for Genzyme, which values the US biotech at about $18.5 billion. Not surprisingly, the Genzyme board unanimously rejected the ...
Novartis has completed its acquisition of a 52% stake in the eyecare firm Alcon from Nestlé.
The Swiss pharma giant paid $28.3 billion for the stake, taking its total share of Alcon up to 77%. It had bought a 25% stake in the company from Nestlé ...
Shares in Trubion Pharmaceuticals jumped nearly 50% on news of a definitive agreement to be acquired by Emergent BioSolutions, the US company specialising in immunobiotics for biodefence applications and commercial use against infectious diseases. ...
Novartis has secured regulatory clearance in the EU and Canada for its proposed acquisition of Alcon, subject to the company selling off certain ophthalmological and consumer eyecare products that were raising competition concerns, clearing further ...
Endo Pharmaceuticals has moved to optimise its Opana pain management franchise and open up new drug delivery and formulation possibilities across its pipeline with an agreement to acquire drug development partner Penwest Pharmaceuticals for $5.00 ...
